Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2265278/incyte-s-incy-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2265278
Apr 30, 2024 - Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
0
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2267253/alkermes-alks-q1-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2267253
May 02, 2024 - Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
0
Pages: 1
Page 1